FINANCIAL INFORMATION

Comparison of the Three Months Ended March 31, 2018 and 2017

Revenue

Total revenue increased to US$32.5 million for the three months ended March 31, 2018, from nil
for the three months ended March 31, 2017. The following table summarizes the components of
revenue for the three months ended March 31, 2018 and 2017, respectively:

Product revenue ....................................
Collaboration revenue ..........................

Reimbursement of research and

development costs...........................

Research and development service

revenue...........................................

Three Months Ended March 31,

Change

2018

2017

$

%

(US dollars in thousands)

$

23,250

$

— $

23,250

7,555

1,739

—

—

7,555

1,739

Total .....................................................

$

32,544

$

— $

32,544

—

—

—

—

Net product revenue was US$23.3 million for the three months ended March 31, 2018, which
related to sales of ABRAXANE威, REVLIMID威 and VIDAZA威 in China. We began recognizing
product revenue with sales to our distributor in China in September 2017 following the closing of our
strategic collaboration with Celgene. VIDAZA威 was launched in China in February 2018. We had no
product revenue for the three months ended March 31, 2017.

Collaboration revenue from the Celgene collaboration totaled US$9.3 million for the three
months ended March 31, 2018, and was comprised of US$7.6 million for the reimbursement of
research and development costs for the clinical trials that Celgene has opted into and US$1.7 million
related to the recognition of deferred revenue for upfront fees allocated to undelivered research and
development services. There was no collaboration revenue for the three months ended March 31, 2017.

Cost of Sales

Cost of sales increased to US$4.6 million for the three months ended March 31, 2018 from nil
for the three months ended March 31, 2017. Cost of sales for the three months ended March 31, 2018
consisted entirely of the cost of products purchased from Celgene and distributed in the PRC. We had
no product sales for the three months ended March 31, 2017.

— 270 —

